ANAPC5

Across TCGA pan-cancer cohorts, ANAPC5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ANAPC5 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ANAPC5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANAPC5 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where ANAPC5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.168	0.500	.007	35	view →
LUAD	OS	Tertile	All	1.000	0.879	.008	25	view →
HNSC	DFS	Median	III,IV	0.665	0.911	.002	19	view →
CCRCC	DFS	Median	III,IV	0.355	0.828	<.001	9	view →
LSCC	DFS	Median	II,III,IV	0.498	0.919	.037	3	view →
GBM	DFS	Tertile	All	0.481	0.229	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ANAPC5–PDAC (DFS)

Open the PDAC breakdown →